vs
Side-by-side financial comparison of American Electric Power (AEP) and Bausch Health Companies Inc. (BHC). Click either name above to swap in a different company.
American Electric Power is the larger business by last-quarter revenue ($5.1B vs $2.8B, roughly 1.8× Bausch Health Companies Inc.). American Electric Power runs the higher net margin — 12.0% vs -3.7%, a 15.7% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 6.2%). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -0.3%).
American Electric Power Company, Inc., an electric public utility holding company, engages in the generation, transmission, and distribution of electricity for sale to retail and wholesale customers in the United States. It operates through Vertically Integrated Utilities, Transmission and Distribution Utilities, AEP Transmission Holdco, and Generation & Marketing segments. The company generates electricity using coal and lignite, natural gas, nuclear, hydro, solar, wind, and other energy sou...
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
AEP vs BHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.1B | $2.8B |
| Net Profit | $605.2M | $-103.0M |
| Gross Margin | — | — |
| Operating Margin | 22.1% | 17.0% |
| Net Margin | 12.0% | -3.7% |
| Revenue YoY | 6.2% | 9.3% |
| Net Profit YoY | -9.1% | -205.1% |
| EPS (diluted) | $1.06 | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.1B | $2.8B | ||
| Q3 25 | $6.0B | $2.7B | ||
| Q2 25 | $5.1B | $2.5B | ||
| Q1 25 | $5.6B | $2.3B | ||
| Q4 24 | $4.8B | $2.6B | ||
| Q3 24 | $5.5B | $2.5B | ||
| Q2 24 | $4.7B | $2.4B | ||
| Q1 24 | $5.1B | $2.2B |
| Q4 25 | $605.2M | $-103.0M | ||
| Q3 25 | $1.0B | $179.0M | ||
| Q2 25 | $1.3B | $148.0M | ||
| Q1 25 | $802.2M | $-58.0M | ||
| Q4 24 | $665.9M | $98.0M | ||
| Q3 24 | $961.7M | $-85.0M | ||
| Q2 24 | $342.5M | $10.0M | ||
| Q1 24 | $1.0B | $-64.0M |
| Q4 25 | 22.1% | 17.0% | ||
| Q3 25 | 25.5% | 23.1% | ||
| Q2 25 | 27.7% | 17.5% | ||
| Q1 25 | 22.8% | 12.2% | ||
| Q4 24 | 23.0% | 21.8% | ||
| Q3 24 | 24.7% | 12.7% | ||
| Q2 24 | 14.7% | 16.2% | ||
| Q1 24 | 23.1% | 13.1% |
| Q4 25 | 12.0% | -3.7% | ||
| Q3 25 | 16.8% | 6.7% | ||
| Q2 25 | 25.5% | 5.8% | ||
| Q1 25 | 14.2% | -2.6% | ||
| Q4 24 | 14.0% | 3.8% | ||
| Q3 24 | 17.6% | -3.4% | ||
| Q2 24 | 7.4% | 0.4% | ||
| Q1 24 | 19.8% | -3.0% |
| Q4 25 | $1.06 | $-0.30 | ||
| Q3 25 | $1.81 | $0.48 | ||
| Q2 25 | $2.29 | $0.40 | ||
| Q1 25 | $1.50 | $-0.16 | ||
| Q4 24 | $1.24 | $0.24 | ||
| Q3 24 | $1.80 | $-0.23 | ||
| Q2 24 | $0.64 | $0.03 | ||
| Q1 24 | $1.90 | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $417.0M | $1.3B |
| Total DebtLower is stronger | $47.3B | $20.8B |
| Stockholders' EquityBook value | $31.1B | $-554.0M |
| Total Assets | $114.5B | $26.4B |
| Debt / EquityLower = less leverage | 1.52× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $417.0M | $1.3B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $439.3M | $1.7B | ||
| Q1 25 | $463.6M | $1.1B | ||
| Q4 24 | $418.3M | $1.2B | ||
| Q3 24 | $474.4M | $719.0M | ||
| Q2 24 | $428.2M | $595.0M | ||
| Q1 24 | $447.7M | $733.0M |
| Q4 25 | $47.3B | $20.8B | ||
| Q3 25 | $46.1B | $21.0B | ||
| Q2 25 | $44.5B | $21.7B | ||
| Q1 25 | $43.0B | $21.5B | ||
| Q4 24 | $42.6B | $21.6B | ||
| Q3 24 | $42.0B | $21.5B | ||
| Q2 24 | $42.1B | $21.7B | ||
| Q1 24 | $39.8B | $22.1B |
| Q4 25 | $31.1B | $-554.0M | ||
| Q3 25 | $30.4B | $-565.0M | ||
| Q2 25 | $29.9B | $-764.0M | ||
| Q1 25 | $27.3B | $-1.2B | ||
| Q4 24 | $26.9B | $-1.3B | ||
| Q3 24 | $26.6B | $-1.2B | ||
| Q2 24 | $26.1B | $-1.2B | ||
| Q1 24 | $25.8B | $-1.1B |
| Q4 25 | $114.5B | $26.4B | ||
| Q3 25 | $110.3B | $26.8B | ||
| Q2 25 | $107.8B | $27.3B | ||
| Q1 25 | $104.4B | $26.4B | ||
| Q4 24 | $103.1B | $26.5B | ||
| Q3 24 | $100.1B | $26.5B | ||
| Q2 24 | $99.6B | $26.5B | ||
| Q1 24 | $97.7B | $26.9B |
| Q4 25 | 1.52× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 1.49× | — | ||
| Q1 25 | 1.57× | — | ||
| Q4 24 | 1.58× | — | ||
| Q3 24 | 1.58× | — | ||
| Q2 24 | 1.61× | — | ||
| Q1 24 | 1.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8B | $495.0M |
| Free Cash FlowOCF − Capex | — | $403.0M |
| FCF MarginFCF / Revenue | — | 14.4% |
| Capex IntensityCapex / Revenue | — | 3.3% |
| Cash ConversionOCF / Net Profit | 3.00× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8B | $495.0M | ||
| Q3 25 | $2.5B | $405.0M | ||
| Q2 25 | $1.2B | $289.0M | ||
| Q1 25 | $1.4B | $211.0M | ||
| Q4 24 | $1.7B | $601.0M | ||
| Q3 24 | $2.2B | $405.0M | ||
| Q2 24 | $1.5B | $380.0M | ||
| Q1 24 | $1.4B | $211.0M |
| Q4 25 | — | $403.0M | ||
| Q3 25 | $2.2B | $314.0M | ||
| Q2 25 | — | $190.0M | ||
| Q1 25 | — | $96.0M | ||
| Q4 24 | — | $495.0M | ||
| Q3 24 | — | $334.0M | ||
| Q2 24 | — | $302.0M | ||
| Q1 24 | — | $129.0M |
| Q4 25 | — | 14.4% | ||
| Q3 25 | 36.3% | 11.7% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 13.3% | ||
| Q2 24 | — | 12.6% | ||
| Q1 24 | — | 6.0% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | 5.0% | 3.4% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | 0.0% | 2.8% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 3.8% |
| Q4 25 | 3.00× | — | ||
| Q3 25 | 2.46× | 2.26× | ||
| Q2 25 | 0.95× | 1.95× | ||
| Q1 25 | 1.81× | — | ||
| Q4 24 | 2.59× | 6.13× | ||
| Q3 24 | 2.26× | — | ||
| Q2 24 | 4.27× | 38.00× | ||
| Q1 24 | 1.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AEP
| Transmissionand Distribution Utilities Revenues | $1.5B | 29% |
| Electric Generation Transmission Distribution Revenues | $956.6M | 19% |
| Electricity Transmission And Distribution Revenues | $931.8M | 18% |
| Industrial | $685.8M | 14% |
| Marketing Competitive Retailand Renewable | $438.3M | 9% |
| Wholesale Generation | $231.1M | 5% |
| Wholesale Transmission | $113.6M | 2% |
| Other | $110.2M | 2% |
| Electric Transmission | $103.4M | 2% |
| Other Retail | $60.1M | 1% |
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
